Cann Group granted TGA GMP for Mildura facility

Yesterday, Rua Bioscience's (NZX: RUA) partner, Cann Group (ASX: CAN), was granted a GMP licence to manufacture therapeutic goods which includes GMP testing at its Mildura facility. In combination with the licences and permits issued by the Office of Drug Control (ODC) of Australia earlier this year, the Mildura GMP Licence enables Cann to manufacture Active Pharmaceutical Ingredients (API) and hard capsules and to conduct GMP-approved activities at the facility's existing chemistry and microbiology laboratories. Cann is Rua's Australian strategic manufacturing, supply and technical services partner as a result of Rua's purchase of Zalm Therapeutics. Cann's new AUD $120m cultivation and processing facility at Mildura is considered one of the largest and most advanced in Australasia. The first stage of its construction is now operational and capable of producing 12,500 kilograms of dried cannabis flower per year. When complete, capacity at the 13.5-hectare facility will grow up to 70,000 kilograms. In a capital-light strategy, Gisborne-based Rua is leveraging this scale to deliver a range of medicinal cannabis products to multiple export markets. Ends. For more information, please contact: Kerry Donovan Communications Manager Rua Bioscience Email: kerry.donovan@ruabio.com Phone: 021 128 7689 End CA:00394729 For:RUA Type:GENERAL Time:2022-07-01 11:20:48